Inhibitors of 11β -HSD1: A potential treatment for the metabolic syndrome

Current Topics in Medicinal Chemistry

Volumn 8, Issue 17, 2008, Pages 1508-1523

  St Jean Jr , David J ^a   Wang, Minghan ^a   Fotsch, Christopher ^a  

^a AMGEN INC   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Cortisol; Cushing's syndrome; Glucocorticoid excess; HPA axis; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; 2 AMINO ADAMANTYL DERIVATIVE; 2 ANILINOTHIAZOLONE; 2 ANILINOTHIAZOLONE DERIVATIVE; 2 CYCLOALKYLAMINOTHIAZOLONE DERIVATIVE; 3 CHLORO 2 METHYL N [4 [2 (4 METHYL 1 PIPERAZINYL) 2 OXOETHYL] 2 THIAZOLYL]BENZENESULFONAMIDE; ANILINE DERIVATIVE; CARBENOXOLONE; CYCLOALKYLAMINO DERIVATIVE; GLYCYRRHETINIC ACID; INCB 13739; OXIDOREDUCTASE INHIBITOR; PERHYDROQUINOLYLBENZAMIDE; PF 915275; THIAZOLE DERIVATIVE; TRIFLUOROMETHYL DERIVATIVE; UNCLASSIFIED DRUG; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ENZYME INHIBITOR;

CLINICAL TRIAL; DIABETIC OBESITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; GLUCONEOGENESIS; HUMAN; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; ENZYME INHIBITORS; HUMANS; METABOLIC SYNDROME X;

EID: 59149094004     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608786413528     Document Type: Review

References (71)

1. Alberti, G.; Zimmet, P.; Shaw, J.; Grundy, S. M. (2006). The IDF consensus worldwide definition of the Metabolic Syndrome, International Diabetes Foundation, 2006; pp. 23.
2. Grundy, S. M.; Brewer, H. B., Jr.; Cleeman, J. I.; Smith, S. C., Jr.; Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109, 433-438.
3. Dunn, J. F.; Nisula, B. C.; Rodbard, D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 1981, 53, 58-68.
4. Walker, E. A.; Stewart, P. M. 11β-Hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol. Metab. 2003, 14, 334-339.
5. Hanson, R. W.; Reshef, L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu. Rev. Biochem. 1997, 66, 581-611.
6. Bujalska, I. J.; Kumar, S.; Hewison, M.; Stewart, P. M. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 1999, 140, 3188-3196.
7. Masuzaki, H.; Paterson, J.; Shinyama, H.; Morton, N. M.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294, 2166-2170.
8. Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R.; Seckl, J. R.; Mullins, J. J. 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. USA 1997, 94, 14924-14929.
9. Morton, N. M.; Paterson, J. M.; Masuzaki, H.; Holmes, M. C.; Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.; Seckl, J. R. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53, 931-938.
10. Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux, A.; Mullins, J. J.; Seckl, J. R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 2001, 276, 41293-41300.
11. Rask, E.; Olsson, T.; Soderberg, S.; Andrew, R.; Livingstone, D. E. W.; Johnson, O.; Walker, B. R. Tissue-specific dysregulation of cortisol metabolism in human obesity. J. Clin. Endocrinol. Metab. 2001, 86, 1418-1421.
12. Kannisto, K.; Pietiläinen, K. H.; Ehrenborg, E.; Rissanen, A.; Kaprio, J.; Hamsten, A.; Yki-Järvinen, H. Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: Studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 2004, 89, 4414-4421.
13. Arnaldi, G.; Angeli, A.; Atkinson, A. B.; Bertagna, X.; Cavagnini, F.; Chrousos, G. P.; Fava, G. A.; Findling, J. W.; Gaillard, R. C.; Grossman, A. B.; Kola, B.; Lacroix, A.; Mancini, T.; Mantero, F.; Newell-price, J.; Nieman, L. K.; Sonino, N.; Vance, M. L.; Giustina, A.; Boscaro, M. Diagnosis and complications of Cushing's syndrome: A consensus statement. J. Clin. Endocrinol. Metab. 2003, 88, 5593-5602.
14. Pivonello, R.; Faggiano, A.; Lombardi, G.; Colao, A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol. Metab. Clin. North Am. 2005, 34, 327-339.
15. Wei, L.; MacDonald, T. M.; Walker, B. R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann. Intern. Med. 2004, 141, 764-770.
16. Faggiano, A.; Pivonello, R.; Spiezia, S.; De Martino, M. C.; Filippella, M.; Di Somma, C.; Lombardi, G.; Colao, A. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J. Clin. Endocrinol. Metab. 2003, 88, 2527-2533.
17. Chu, J. W.; Matthias, D. F.; Belanoff, J.; Schatzberg, A.; Hoffman, A. R.; Feldman, D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. 2001, 86, 3568-3573.
18. Nieman, L. K.; Chrousos, G. P.; Kellner, C.; Spitz, I. M.; Nisula, B. C.; Cutler, G. B.; Merriam, G. R.; Bardin, C. W.; Loriaux, D. L. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU 486. J. Clin. Endocrinol. Metab. 1985, 61, 536-540.
19. Lamberts, S. W.; Koper, J. W.; de, J. F. H. The endocrine effects of long-term treatment with mifepristone (RU 486). J. Clin. Endocrinol. Metab. 1991, 73, 187-191.
20. Pavlova, S. I.; Uteshev, B. S.; Sergeev, A. V. Licorice root: possible mechanisms of antitoxicant, anti-carcinogen, and antitumor properties (A Review). Pharm. Chem. J. 2003, 37, 314-317.
21. Diederich, S.; Grossmann, C.; Hanke, B.; Quinkler, M.; Herrmann, M.; Bahr, V.; Oelkers, W. In the search for specific inhibitors of human 11β-hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur. J. Endocrinol. 2000, 142, 200-207.
22. Nuotio-Antar, A. M.; Hachey, D. L.; Hasty, A. H. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice. Am. J. Physiol. Endocrinol. Metab. 2007, 293, E1517-1528.
23. Walker, B. R.; Connacher, A. A.; Lindsay, R. M.; Webb, D. J.; Edwards, C. R. W. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 1995, 80, 3155-3159.
24. Andrews, R. C.; Rooyackers, O.; Walker, B. R. Effects of the 11β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab. 2003, 88, 285-291.
25. Kotelevtsev, Y.; Brown, R. W.; Fleming, S.; Kenyon, C.; Edwards, C. R. W.; Seckl, J. R.; Mullins, J. J. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 1999, 103, 683-689.
26. Sandeep, T. C.; Yau, J. L. W.; MacLullich, A. M. J.; Noble, J.; Deary, I. J.; Walker, B. R.; Seckl, J. R. 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. USA 2004, 101, 6734-6739.
27. Fotsch, C.; Askew, B. C.; Chen, J. J. 11β-hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases. Expert Opin. Ther. Pat. 2005, 15, 289-303.
28. Webster, S. P.; Pallin, D. P. 11β-hydroxysteroid dehydrogenase-1 as therapeutic agents. Expert Opin. Ther. Pat. 2007, 17, 1407-1422.
29. Boyle, C. D.; Kowalski, T. J.; Zhang, L. 11β-hydroxysteroid dehydrogenase type 1 inhibitors. Annu. Rep. Med. Chem. 2006, 41, 127-140.
30. Wamil, M.; Seckl, J. R. Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discovery Today 2007, 12, 504-520.
31. Barf, T.; Williams, M. Recent progress in 11β-hydroxysteroid dehydrogenase type 1 (11-β-HSD1) inhibitor development. Drugs of the Future 2006, 31, 231-243.
32. Coppola, G. M.; Kukkola, P. J.; Stanton, J. L.; Neubert, A. D.; Marcopulos, N.; Bilci, N. A.; Wang, H.; Tomaselli, H. C.; Tan, J.; Aicher, T. D.; Knorr, D. C.; Jeng, A. Y.; Dardik, B.; Chatelain, R. E. Perhydroquinolylbenzamides as Novel Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1. J. Med. Chem. 2005, 48, 6696-6712.
33. Yeh, V. S. C.; Patel, J. R.; Yong, H.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Stolarik, D.; Imade, H.; Beno, D.; Brune, M.; Jacobson, P.; Sham, H.; Link, J. T. Synthesis and biological evaluation of heterocycle containing adamantane 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5414-5419.
34. Yeh, V. S. C.; Kurukulasuriya, R.; Madar, D.; Patel, J. R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Jacobson, P.; Sham, H. L.; Link, J. T. Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements. Bioorg. Med. Chem. Lett. 2006, 16, 5408-5413.
35. Yeh, V. S. C.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Stolarik, D.; Imade, H.; Shapiro, R.; Knourek-Segel, V.; Bush, E.; Wilcox, D.; Nguyen, P. T.; Brune, M.; Jacobson, P.; Link, J. T. Discovery of orally active butyrolactam 11β-HSD1 inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5555-5560.
36. Sorensen, B.; Rohde, J.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Pan, L.; Deng, X.; Stolarik, D.; Frevert, E. U.; Jacobson, P.; Link, J. T. Adamantane 11-β-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction. Bioorg. Med. Chem. Lett. 2006, 16, 5958-5962.
37. Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jacobson, P.; Link, J. T. Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 527-532.
38. Rohde, J. J.; Pliushchev, M. A.; Sorensen, B. K.; Wodka, D.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K. M.; Chiou, W. J.; Pan, L.; Deng, X.; Chovan, L. E.; Ramaiya, A.; Mullally, M.; Henry, R. F.; Stolarik, D. F.; Imade, H. M.; Marsh, K. C.; Beno, D. W. A.; Fey, T. A.; Droz, B. A.; Brune, M. E.; Camp, H. S.; Sham, H. L.; Frevert, E. U.; Jacobson, P. B.; Link, J. T. Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-N-(adamant-2-yl) Acetamide 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors. J. Med. Chem. 2007, 50, 149-164.
39. Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-aminopyridin-2-yl)-amide (PF-915275), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 2008, 324, 299-305.
40. Olson, S.; Aster, S. D.; Brown, K.; Carbin, L.; Graham, D. W.; Hermanowski-Vosatka, A.; LeGrand, C. B.; Mundt, S. S.; Robbins, M. A.; Schaeffer, J. M.; Slossberg, L. H.; Szymonifka, M. J.; Thieringer, R.; Wright, S. D.; Balkovec, J. M. Adamantyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359-4362.
41. Gu, X.; Dragovic, J.; Koo, G. C.; Koprak, S. L.; LeGrand, C.; Mundt, S. S.; Shah, K.; Springer, M. S.; Tan, E. Y.; Thieringer, R.; Hermanowski-Vosatka, A.; Zokian, H. J.; Balkovec, J. M.; Waddell, S. T. Discovery of 4-heteroarylbicyclo[2.2.2] octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome. Bioorg. Med. Chem. Lett. 2005, 15, 5266-5269.
42. Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11 -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J. Exp. Med. 2005, 202, 517-527.
43. Barf, T.; Vallgårda, J.; Emond, R.; Häggström, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Rönquist-Nii, Y.; Öhman, B.; Alberts, P.; Abrahmsén, L. Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11β-Hydroxysteroid Dehydrogenase Type 1. J. Med. Chem. 2002, 45, 3813-3815.
44. St. Jean, D. J., Jr.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.; Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. 2-(S)-Phenethyl-aminothiazolones as Potent, Orally Efficacious Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1. J. Med. Chem. 2007, 50, 429-432.
45. Hosfield, D. J.; Wu, Y.; Skene, R. J.; Hilgers, M.; Jennings, A.; Snell, G. P.; Aertgeerts, K. Conformational Flexibility in Crystal Structures of Human 11 -Hydroxysteroid Dehydrogenase Type I Provide Insights into Glucocorticoid Interconversion and Enzyme Regulation. J. Biol. Chem. 2005, 280, 4639-4648.
46. Zhang, J.; Osslund, T. D.; Plant, M. H.; Clogston, C. L.; Nybo, R. E.; Xiong, F.; Delaney, J. M.; Jordan, S. R. Crystal Structure of Murine 11β-Hydroxysteroid Dehydrogenase 1: An Important Therapeutic Target for Diabetes. Biochemistry 2005, 44, 6948-6957.
47. Yuan, C.; St. Jean, D. J., Jr.; Liu, Q.; Cai, L.; Li, A.; Han, N.; Moniz, G.; Askew, B.; Hungate, R. W.; Johansson, L.; Tedenborg, L.; Pyring, D.; Williams, M.; Hale, C.; Chen, M.; Cupples, R.; Zhang, J.; Jordan, S.; Bartberger, M. D.; Sun, Y.; Emery, M.; Wang, M.; Fotsch, C. The Discovery of 2-Anilinothiazolones as 11β-HSD1 Inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 6056-6061.
48. Johansson, L. Fotsch, C.; Bartberger, M. D.; Castro, V. M.; Chen, M.; Emery, M.; Gustafsson, S.; Hale, C.; Hickman, D.; Homan, E.; Jordan, S. R.; Komorowski, R.; Li, A.; McRae, K.; Moniz, G.; Matsumoto, G.; Orihuela, C.; Palm, G.; Veniant, M.; Wang, M.; Williams, M.; Zhang, J. 2-Amino-1,3-thiazol-4(5H)-ones as Potent and Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Enzyme-Ligand Co-Crystal Structure and Demonstration of Pharmacodynamic Effects in C57Bl/6 Mice. J. Med. Chem. 2008, 51, 2933-2943.
49. i of 140 nM.
50. Ogg, D.; Elleby, B.; Norström, C.; Stefansson, K.; Abrahmsén, L.; Oppermann, U.; Svensson, S. The Crystal Structure of Guinea Pig 11β-Hydroxysteroid Dehydrogenase Type 1 Provides a Model for Enzyme-Lipid Bilayer Interactions. J. Biol. Chem. 2005, 280, 3789-3794.
51. Unpublished results.
52. Hale, C.; Veniant, M.; Wang, Z.; Chen, M.; McCormick, J.; Cupples, R.; Hickman, D.; Min, X.; Sudom, A.; Xu, H.; Matsumoto, G.; Fotsch, C.; St. Jean, D. J., Jr.; Wang, M. Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor. Chem. Biol. Drug Des. 2008, 71, 36-44.
53. von Geldern, T. W.; Tu, N.; Kym, P. R.; Link, J. T.; Jae, H.-S.; Lai, C.; Apelqvist, T.; Rhonnstad, P.; Hagberg, L.; Koehler, K.; Grynfarb, M.; Goos-Nilsson, A.; Sandberg, J.; Oesterlund, M.; Barkhem, T.; Hoeglund, M.; Wang, J.; Fung, S.; Wilcox, D.; Nguyen, P.; Jakob, C.; Hutchins, C.; Faernegrdh, M.; Kauppi, B.; Oehman, L.; Jacobson, P. B. Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes. J. Med. Chem. 2004, 47, 4213-4230.
54. Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes, M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci. USA 2004, 101, 7088-7093.
55. Veniant, M. H., C.; Komorowski, R.; Chen, M. M.; St. Jean, D. J., Jr.; Fotsch, C.; Wang, M. Time of day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes. Metabol. 2008, in press.
56. Harris, H. J.; Kotelevtsev, Y.; Mullins, J. J.; Seckl, J. R.; Holmes, M. C. Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (112b-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary-adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 2001, 142, 114-120.
57. Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingström, G.; Larsson, C.; Rönquist-Nii, Y.; Öehman, B.; Abrahmsén, L. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45, 1528-1532.
58. Livingstone, D. E. W.; Walker, B. R. Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J. Pharmacol. Exp. Ther. 2003, 305, 167-172.
59. Wess, L. Biovitrum replenishes. BioCentury 2005, March 28, A13.
60. "AMG 221 is an orally-administered agent being evaluated for treatment of metabolic disorders, including type 2 diabetes." Retrieved 3/21/ 2008, from http://www.amgen.com/science/ pipe_AMG221.html
61. Courtney, R.; Stewart, P. M.; Toh, M.; Ndongo, M. N.; Calle, R. A.; Hirshberg, B. Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor. J. Clin. Endocrinol. Metab. 2008, 93, 550-556.
62. Pfizer. "NCT00427401: A Study To Evaluate PF-00915275 In Subjects With Type 2 Diabetes Mellitus For 4-Weeks." from www.clinicaltrials.gov
63. Incyte, Incyte presentation. 26th annual JPMorgan healthcare conference 2008.
64. Huber, R. 11β-HSD1 inhibitors for type 2 diabetes: a systematic development strategy to assess pharmacodynamic activity and obtain proof-of-concept in man. IBC's Targeting metabolic syndrome, Boston, MA 2007, February 28.
65. Incyte, Incyte corporation presentation. 2007 UBS global life sciences conference 2007.
66. "Incyte's Product Pipeline." Retrieved 3/21/2008, from http://www.incyte.com/drugs_product_pipeline.html.
67. Duplomb, L.; Lee, Y.; Wang, M.-Y.; Park, B. H.; Takaishi, K.; Agarwal, A. K.; Unger, R. H. Increased expression and activity of 11β-HSD-1 in diabetic islets and prevention with troglitazone. Biochem. Biophys. Res. Commun. 2004, 313, 594-599.
68. Abdallah, B. M.; Beck-Nielsen, H.; Gaster, M. Increased expression of 11β-hydroxysteroid dehydrogenase type I in type 2 diabetic myotubes. Eur. J. Clin. Invest. 2005, 35, 627-634.
69. Yau, J. L.; Noble, J.; Kenyon, C. J.; Hibberd, C.; Kotelevtsev, Y.; Mullins, J. J.; Seckl, J. R. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc. Natl. Acad. Sci. USA 2001, 98, 4716-4721.
70. Walker, B. R.; Seckl, J. R. 11β-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin. Ther. Targets 2003, 7, 771-783.
71. Rocha, B. A. (2006). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibition prolonged memory retention in mice. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006.